Hit and Run: Bilateral Massive Intraocular Lymphomatous Infiltration after CAR-T Therapy

Abou-Samra, Abdullah; McTavish, Sloane; Whitehair, Rachel; Shildkrot, Yevgeniy

doi:10.1080/09273948.2023.2191713

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several case reports have brought attention to the recurrence of hematological malignancies within the eye following CD19 CAR-T-cell therapy, despite successful control of the central nervous system and the rest of the body 35 , 36 , 45 . It is suggested that insufficient anti-CD19 CAR-T cells may enter the eye, allowing neoplastic B cells to persist.…”

Section: Ocular Adverse Events In Chimeric Antigen Receptor T-cell Th...mentioning

confidence: 99%

See 1 more Smart Citation

Adverse events associated with chimeric antigen receptor T-Cell therapy in ophthalmology: a narrative review

Sarwar,

Riaz,

Ali

et al. 2024

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Chimeric antigen receptors are synthetically produced receptors engineered to engage with target cells with high specificity. These cells are created by inserting an artificial T-cell receptor into an immunoglobulin’s antigen-binding region, allowing the cells to combine and target specific antigens. The use of chimeric antigen receptor (CAR) T-cell therapy has been a remarkable achievement in the field of immunotherapy, particularly in the treatment of ophthalmic tumors like retinoblastoma and uveal melanoma. However, there are some documented side effects, such as cytokine release syndrome (CRS) and immunological effector cell-associated neurotoxicity syndrome (ICANS). Additionally, ocular side effects such as blurred vision, vision impairment, and intraocular infections are also concerning and require further evaluation. This review highlights the advances made in chimeric antigen receptor (CAR) immunotherapy, including its structure and manufacture, as well as relevant clinical discoveries and associated adverse effects. By identifying the gaps in current research, this analysis provides insights into potential strategies and solutions for addressing some of the most severe side effects.

show abstract

Section: Ocular Adverse Events In Chimeric Antigen Receptor T-cell Th...mentioning

confidence: 99%

“…Due to the immune-privileged location of the eye, there is a possibility of intraocular relapse despite effective CAR-T-cell response in the bone marrow and CNS 34 , 35 , 55 . Physicians should consider screening with eye examinations before therapy to identify at-risk patients.…”

Section: Strategies and Solutionsmentioning

confidence: 99%

Adverse events associated with chimeric antigen receptor T-Cell therapy in ophthalmology: a narrative review

Sarwar,

Riaz,

Ali

et al. 2024

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

Ocular adverse events following CAR‐T cell therapy: A pharmacovigilance study and systematic review

Frey,

Cherniawsky,

Etminan

2024

European J of Haematology

View full text Add to dashboard Cite

The rise of immuno‐oncology, including the use of chimeric antigen receptor T‐cell (CAR‐T) therapy is bringing in a new wave of cancer treatments, particularly in hematologic malignancies. However, data on their adverse events, particularly of the eye, is under‐reported. To assess the ocular adverse events associated with the six FDA‐approved CAR‐T cell therapies, a disproportionality analysis utilizing the FAERS database was conducted from the first quarter of 2017 to the third quarter of 2023, as well as a systematic review of case reports of ocular events following CAR‐T cell therapy up to December 20, 2023. A total of 53 ocular adverse events were identified from the FDAs FAERS database. The adverse events most frequently observed were mydriasis and xerophthalmia with tisagenlecleucel (Kymriah). The systematic review resulted in 8 case reports encompassing 19 patients which included a total of 27 events. This study demonstrates the importance of anticipation of potential ocular adverse events by ophthalmologists and oncologists as they can greatly contribute to morbidity in patients with cancer.

show abstract

Hit and Run: Bilateral Massive Intraocular Lymphomatous Infiltration after CAR-T Therapy

Cited by 2 publications

References 14 publications

Adverse events associated with chimeric antigen receptor T-Cell therapy in ophthalmology: a narrative review

Adverse events associated with chimeric antigen receptor T-Cell therapy in ophthalmology: a narrative review

Ocular adverse events following CAR‐T cell therapy: A pharmacovigilance study and systematic review

Contact Info

Product

Resources

About